Lipoatrophic diabetes is a type of diabetes mellitus presenting with severe lipodystrophy in addition to the traditional signs of diabetes. See also
Familial partial lipodystrophy
Congenital generalized lipodystrophy

External links

Iglesias P, Alvarez Fidalgo P, Codoceo R, Díez J (2004). "Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations". Endocr J. 51 (3): 279–86. doi:10.1507/endocrj.51.279. PMID 15256772. Morse A, Whitaker M (2000). "Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report". J Reprod Med. 45 (10): 850–2. PMID 11077638. Meyer L, Hadjadj S, Guerci B, Delbachian I, Ziegler O, Drouin P (1998). "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion". Diabetes Metab. 24 (6): 544–6. PMID 9932222.
After preliminary investigation revealed that the outbreak was linked to intake of tryptophan, the U.S. Food and Drug Administration (FDA) recalled tryptophan supplements in 1989 and banned most public sales in 1990, with other countries following suit. This  FDA restriction was loosened in 2001, and fully lifted in 2005. Since the initial ban on L-tryptophan, a normal metabolite of the compound in mammals, 5-hydroxtryptophan (5-HTP) has become a popular replacement dietary supplement. See also
Toxic oil syndrome

References


== External links ==